Anixa Biosciences, Inc. (ANIX)
- Previous Close
3.1800 - Open
3.2500 - Bid 3.1900 x 100
- Ask 3.2400 x 100
- Day's Range
3.1011 - 3.3200 - 52 Week Range
2.7500 - 5.1300 - Volume
108,206 - Avg. Volume
118,485 - Market Cap (intraday)
102.373M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3400 - Earnings Date Mar 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
www.anixa.comRecent News: ANIX
Performance Overview: ANIX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ANIX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ANIX
Valuation Measures
Market Cap
101.44M
Enterprise Value
77.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
471.11
Price/Book (mrq)
4.12
Enterprise Value/Revenue
370.50
Enterprise Value/EBITDA
-6.48
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.09%
Return on Equity (ttm)
-43.02%
Revenue (ttm)
210k
Net Income Avi to Common (ttm)
-10.74M
Diluted EPS (ttm)
-0.3400
Balance Sheet and Cash Flow
Total Cash (mrq)
23.8M
Total Debt/Equity (mrq)
0.69%
Levered Free Cash Flow (ttm)
-3.06M